Investor Announcements - 2018
|
| ||
EKF Diagnostics provides shareholders with the following update on current trading. | ||
| ||
EKF announces that it has signed a private label distribution agreement with McKesson Medical-Surgical Inc., an affiliate of McKesson Corporation – the Fortune Global 500 healthcare distribution specialist and one of the largest companies in the US by revenue – for the Company’s hand-held reagent-free hemoglobin analyzer, the DiaSpect Tm. | ||
| ||
Standard form for notification of major holdings. | ||
| ||
EKF Diagnostics announces exclusive distribution agreement with Asahi Kasei Pharma to market Lucica® Glycated Albumin-L. | ||
| ||
EKF Diagnostics announces an exclusive manufacturing agreement with Oragenics, Inc. in the United States. | ||
| ||
Renalytix AI PLC to develop Artificial Intelligence for early identification and management of kidney disease. | ||
| ||
Standard form for notification of major holdings. | ||
| ||
Further announcement regarding the exclusive license and collaboration agreement with Icahn School of Medicine at Mount Sinai in New York, USA. | ||
| ||
Renalytix AI plc to develop Artificial Intelligence for early identification and management of kidney disease. | ||
| ||
| |||||||
Newsletter
Keep up to date with all our activities, events, exhibitions, promotions, investor news & more.